Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability.

Luo T, Masson K, Jaffe JD, Silkworth W, Ross NT, Scherer CA, Scholl C, Fröhling S, Carr SA, Stern AM, Schreiber SL, Golub TR. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2860-5.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.